New-onset Autoimmune Diseases in Patients with Prurigo Nodularis: A Global-federated Retrospective Cohort Study
DOI:
https://doi.org/10.2340/actadv.v105.43515Keywords:
Prurigo nodularis, autoimmune diseases, psoriasis, cohort, epidemiology, electronic medical recordsAbstract
Prurigo nodularis (PN) has been associated with autoimmune diseases, though longitudinal data are limited. This study investigates the risk of autoimmune disease development in PN patients using a global electronic health record database. This retrospective cohort study analysed data from the Global Collaborative Network within the TriNetX research network. Adults (≥ 18 years) with PN were compared with propensity score-matched controls without PN. Matching considered age, sex, comorbidities, race, and socioeconomic status. Patients with prior autoimmune diseases or cancers were excluded. Incident autoimmune diseases, including systemic lupus erythematosus (SLE), Sjögren’s syndrome, psoriasis, ankylosing spondylitis (AS), rheumatoid arthritis (RA), Crohn’s disease (CD), and ulcerative colitis (UC), were evaluated using hazard ratios (HR). Among 17,963 PN patients and the same amount of matched pairs, PN patients had higher risks for SLE (HR: 2.16, 95% CI: 1.44–3.24), Sjögren’s syndrome (HR: 1.86, 95% CI: 1.33–2.59), and psoriasis (HR: 3.20, 95% CI: 2.58–3.97). Stratified analysis revealed that female PN patients had higher risks for SLE and Sjögren’s syndrome, while psoriasis risk was elevated in both sexes, especially in males. Risks for AS, RA, CD, and UC were not significant. Sensitivity analyses validated these findings. In conclusion, PN is linked to increased risks for SLE, Sjögren’s syndrome, and psoriasis, highlighting the need for proactive screening and management of autoimmune diseases in PN patients.
Downloads
References
Shao Y, Wang D, Zhu Y, Xiao Z, Jin T, Peng L, et al. Molecular mechanisms of pruritus in prurigo nodularis. Front Immunol 2023; 14: 1301817. DOI: https://doi.org/10.3389/fimmu.2023.1301817
McCampbell LE, Zaino ML, Ranpariya M, Patel T, Feldman SR. Systemic medication for the treatment of prurigo nodularis: a systematic review. J Cutan Med Surg 2023; 27: 641–645. DOI: https://doi.org/10.1177/12034754231211797
Williams KA, Huang AH, Belzberg M, Kwatra SG. Prurigo nodularis: pathogenesis and management. J Am Acad Dermatol 2020; 83: 1567–1575. DOI: https://doi.org/10.1016/j.jaad.2020.04.182
Brooks SG, Yosipovitch G. Prurigo nodularis in 2025: current and emerging treatments. Clin Dermatol 2025; S0738-081X(25)00096-3. DOI: https://doi.org/10.1016/j.clindermatol.2025.03.013
Geng RSQ, Sood S, Waked J, Mahmood R, Maliyar K, Sachdeva M, et al. Disease severity and pruritus treatment outcomes in prurigo nodularis: a systematic review of randomized-controlled trials. J Am Acad Dermatol 2025; 93: 263–265. DOI: https://doi.org/10.1016/j.jaad.2025.03.009
Huang AH, Canner JK, Khanna R, Kang S, Kwatra SG. Real-world prevalence of prurigo nodularis and burden of associated diseases. J Invest Dermatol 2020; 140: 480–483.e484. DOI: https://doi.org/10.1016/j.jid.2019.07.697
Woo YR, Wang S, Sohn KA, Kim HS. Epidemiology, comorbidities, and prescription patterns of Korean prurigo nodularis patients: a multi-institution study. J Clin Med 2021; 11. DOI: https://doi.org/10.3390/jcm11010095
Gau S-Y, Lo S-W, Hsu C, Chen S-J, Zuberbier T, Chang H-C. Human papillomavirus infection is associated with increased risk of new-onset hidradenitis suppurativa: a population-based cohort study. J Am Acad Dermatol 2025; 92: 444–451. DOI: https://doi.org/10.1016/j.jaad.2024.10.055
Chang H-C, Lin C-Y, Guo Y-C, Lu H-Y, Lee C-Y, Wu M-C, et al. Association between hidradenitis suppurativa and atopic diseases: a multi-center, propensity-score-matched cohort study. Int J Med Sci 2024; 21: 299–305. DOI: https://doi.org/10.7150/ijms.90086
Chang H-C, Wu C-L, Chiu T-M, Liao W-C, Gau S-Y. Risk of osteoarthritis in patients with hidradenitis suppurativa: a global federated health network analysis. Front Immunol 2023; 14. DOI: https://doi.org/10.3389/fimmu.2023.1285560
Roh YS, Marani M, Choi U, Sutaria N, Parthasarathy V, Deng J, et al. Validation of International Classification of Diseases Tenth Revision code for prurigo nodularis. J Am Acad Dermatol 2022; 87: 482–484. DOI: https://doi.org/10.1016/j.jaad.2021.10.026
Fry L, Baker BS, Powles AV, Engstrand L. Psoriasis is not an autoimmune disease? Exp Dermatol 2015; 24: 241–244. DOI: https://doi.org/10.1111/exd.12572
Liu A, Liao P, Jiang H, Huang S, Li S, Wei JC, et al. COVID-19 vaccination reduces new-onset fibromyalgia risk in survivors. BMC Med 2025; 23: 255. DOI: https://doi.org/10.1186/s12916-025-04069-z
Li CP, Lo SW, Tsai RY, Chang HC, Gau SY. New-onset hidradenitis suppurativa in psoriasis patients: a multi-center, retrospective cohort study. Life (Basel, Switzerland) 2024; 14. DOI: https://doi.org/10.3390/life14060730
Schuler CFt, Billi AC, Maverakis E, Tsoi LC, Gudjonsson JE. Novel insights into atopic dermatitis. J Allergy Clin Immunol 2023; 151: 1145–1154. DOI: https://doi.org/10.1016/j.jaci.2022.10.023
Yang G, Seok JK, Kang HC, Cho YY, Lee HS, Lee JY. Skin barrier abnormalities and immune dysfunction in atopic dermatitis. Int J Mol Sci 2020; 21. DOI: https://doi.org/10.3390/ijms21082867
Vermeer E, Hebing RCF, van de Meeberg MM, Lin M, de Meij TGJ, Struys EA, et al. Oral versus subcutaneous methotrexate in immune-mediated inflammatory disorders: an update of the current literature. Curr Rheumatol Rep 2023; 25: 276–284. DOI: https://doi.org/10.1007/s11926-023-01116-7
Ma F, Gharaee-Kermani M, Tsoi LC, Plazyo O, Chaskar P, Harms P, et al. Single-cell profiling of prurigo nodularis demonstrates immune-stromal crosstalk driving profibrotic responses and reversal with nemolizumab. J Allergy Clin Immunol 2024; 153: 146–160. DOI: https://doi.org/10.1016/j.jaci.2023.07.005
Rendon A, Schäkel K. Psoriasis pathogenesis and treatment. Int J Mol Sci 2019; 20. DOI: https://doi.org/10.3390/ijms20061475
Kwatra SG. Breaking the itch–scratch cycle in prurigo nodularis. N Engl J Med 2020; 382: 757–758. DOI: https://doi.org/10.1056/NEJMe1916733
Jiang Q, Yang G, Xiao F, Xie J, Wang S, Lu L, et al. Role of Th22 Cells in the pathogenesis of autoimmune diseases. Front Immunol 2021; 12: 688066. DOI: https://doi.org/10.3389/fimmu.2021.688066
Gong F, Wu J, Zhou P, Zhang M, Liu J, Liu Y, et al. Interleukin-22 might act as a double-edged sword in type 2 diabetes and coronary artery disease. Mediators Inflamm 2016; 2016: 8254797. DOI: https://doi.org/10.1155/2016/8254797
Daudén E, Castañeda S, Suárez C, García-Campayo J, Blasco AJ, Aguilar MD, et al. Clinical practice guideline for an integrated approach to comorbidity in patients with psoriasis. J Eur Acad Dermatol Venereol 2013; 27: 1387–1404. DOI: https://doi.org/10.1111/jdv.12024
Zheng Y, Li T. Interleukin-22, a potent target for treatment of non-autoimmune diseases. Hum Vaccin Immunother 2018; 14: 2811–2819. DOI: https://doi.org/10.1080/21645515.2018.1509649
Mashiko S, Bouguermouh S, Rubio M, Baba N, Bissonnette R, Sarfati M. Human mast cells are major IL-22 producers in patients with psoriasis and atopic dermatitis. J Allergy Clin Immunol 2015; 136: 351–359.e351. DOI: https://doi.org/10.1016/j.jaci.2015.01.033
Wolk K, Witte E, Wallace E, Döcke WD, Kunz S, Asadullah K, et al. IL-22 regulates the expression of genes responsible for antimicrobial defense, cellular differentiation, and mobility in keratinocytes: a potential role in psoriasis. Eur J Immunol 2006; 36: 1309–1323. DOI: https://doi.org/10.1002/eji.200535503
Belzberg M, Alphonse MP, Brown I, Williams KA, Khanna R, Ho B, et al. Prurigo nodularis is characterized by systemic and cutaneous T helper 22 immune polarization. J Invest Dermatol 2021; 141: 2208–2218.e2214. DOI: https://doi.org/10.1016/j.jid.2021.02.749
Furue M. Regulation of filaggrin, loricrin, and involucrin by IL-4, IL-13, IL-17A, IL-22, AHR, and NRF2: pathogenic implications in atopic dermatitis. Int J Mol Sci 2020; 21. DOI: https://doi.org/10.3390/ijms21155382
Sutaria N, Alphonse MP, Roh YS, Choi J, Parthasarathy V, Deng J, et al. Cutaneous transcriptomics identifies fibroproliferative and neurovascular gene dysregulation in prurigo nodularis compared with psoriasis and atopic dermatitis. J Invest Dermatol 2022; 142: 2537–2540. DOI: https://doi.org/10.1016/j.jid.2022.02.010
Su Z, Zeng YP. Dupilumab-associated psoriasis and psoriasiform manifestations: a scoping review. Dermatology 2023; 239: 646–657. DOI: https://doi.org/10.1159/000530608
Kabbani M, Mboyo Mpita G, Benhadou F. Ustekinumab plus dupilumab in the treatment of concomitant psoriasis and prurigo nodularis. J Eur Acad Dermatol Venereol 2022; 36: e1050–e1051. DOI: https://doi.org/10.1111/jdv.18445
McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med 2011; 365: 2205–2219. DOI: https://doi.org/10.1056/NEJMra1004965
Strazzulla LC, Wang EHC, Avila L, Lo Sicco K, Brinster N, Christiano AM, et al. Alopecia areata: disease characteristics, clinical evaluation, and new perspectives on pathogenesis. J Am Acad Dermatol 2018; 78: 1–12. DOI: https://doi.org/10.1016/j.jaad.2017.04.1141
Yook HJ, Lee JH. Prurigo nodularis: pathogenesis and the horizon of potential therapeutics. Int J Mol Sci 2024; 25: 5164. DOI: https://doi.org/10.3390/ijms25105164
Augustin M, Garbe C, Hagenström K, Petersen J, Pereira MP, Ständer S. Prevalence, incidence and presence of comorbidities in patients with prurigo and pruritus in Germany: a population-based claims data analysis. J Eur Acad Dematol Venereol 2021; 35: 2270–2276. DOI: https://doi.org/10.1111/jdv.17485
Gau SY. Methotrexate use and liver outcomes in psoriasis and rheumatoid arthritis patients: a commentary on “Risk of liver disease in patients with psoriasis, psoriatic arthritis and rheumatoid arthritis receiving methotrexate: A population-based study”. J Am Acad Dermatol 2021; 85: e399–e400. DOI: https://doi.org/10.1016/j.jaad.2021.07.069
Additional Files
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2025 Hui-Chin Chang, Chia-Chi Chang, Yen-Ju Chu, Wei-Ting Hsu, Yun-Feng Li, Yi-Sheng Jhang, Yu-Jung Su, Shiu-Jau Chen, Torsten Zuberbier, Shuo-Yan Gau
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.
Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.
